(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 June 2011 (09.06.2011)

PCT

(10) International Publication Number
WO 2011/067212 A1

(51) **International Patent Classification**:
A61K 31/138 (2006.01) ***A61P 11/06*** (2006.01)
A61K 31/439 (2006.01) ***A61P 11/08*** (2006.01)
A61K 45/06 (2006.01)

(21) **International Application Number**:
PCT/EP2010/068429

(22) **International Filing Date**:
29 November 2010 (29.11.2010)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
0921075.8 1 December 2009 (01.12.2009) GB

(71) **Applicant** *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BAKER, Darrell** [GB/GB]; GlaxoSmithKline, Ironbridge Road, Uxbridge Middlesex UB11 1BS (GB). **BRUCE, Mark** [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage Hertfordshire SG1 2NY (GB). **CRATER, Glenn** [US/US]; GlaxoSmithKline, Five Moore Drive, P O Box 13398, Research Triangle Park, North Carolina 27709-3398 (US). **NOGA, Brian** [US/US]; c/o GlaxoSmithKline, Five Moore Drive, P O Box 13398, Research Triangle Park, North Carolina 27709-3398 (US). **THOMAS, Marian** [GB/GB]; GlaxoSmithKline, Park Road, Ware Hertfordshire SG12 0DJ (GB). **WIRE, Patrick** [US/US]; GlaxoSmithKline, Five Moore Drive, P O Box 13398, Research Triangle Park, North Carolina 27709-3398 (US).

(74) **Agents**: **COOKE, Tracey** et al.; GlaxoSmithKline, Global Patents CN925.1, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2011/067212 A1

(54) **Title**: COMBINATIONS OF A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2 ADRENORECEPTOR AGONIST

(57) **Abstract**: Novel combinations of a muscarinic acetylcholine receptor antagonist and a beta 2 agonist for inhaled administration via the nose or mouth, and methods of using them are provided.